Pulmonx Corp (LUNG) 8-K Current Report: March 5, 2026

Filed: March 5, 2026

Health Care

Surgical & Medical Instruments & Apparatus

Pulmonx Corp (LUNG) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation

Pulmonx Corp 8-K Mar 5, 2026 Event Analysis

Item 1.01 · Entry into a Material Definitive Agreement

• $40M drawn immediately from $60M senior secured term loan facility with Perceptive; 5-year maturity (March 2031), bullet repayment structure
• Interest rate: SOFR (floor 3.75%) + 7.00% margin — currently ~10.75%+ annually; PIK option up to 2% for first 36 months adds to principal
• Remaining $20M available in two $10M tranches tied to revenue milestones: $92.5M TTM revenue (by Q3 2027) and $100M TTM revenue (by Q4 2027)
• Perceptive receives warrants for 1M shares at $1.92 (25% premium to 10-day VWAP); additional warrants issued if delayed draw tranches are funded — meaningful dilution risk
• Prepayment premium up to 10% plus 1.50% exit fee on all repaid principal signals high total cost of capital; minimum liquidity covenant of $4M adds financial flexibility constraint

Item 1.02 · Termination of a Material Definitive Agreement

• Pulmonx fully repaid and terminated its CIBC credit facility on March 2, 2026, replacing it with a new Loan Facility
• No early termination fees or penalties incurred — clean exit from the CIBC agreement dating back to March 2021
• Termination signals a complete refinancing event; new Loan Facility terms will govern the company's debt structure going forward

Item 2.03 · Creation of a Direct Financial Obligation

• Item 2.03 covers new debt/financial obligations; actual terms (amount, rate, maturity) not visible in truncated text provided
• Full details likely cross-referenced to another item (typically Item 1.01) — review complete filing for loan terms

Other Pulmonx Corp 8-K Filings

8-K Mar 4, 2026

Get deeper insights on Pulmonx Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.